Top

Published in:

01-08-2014 | Colorectal Cancer

Metastatic Colorectal Cancer: Survival Comparison of Hepatic Resection Versus Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Authors: Aaron U. Blackham, MD, Gregory B. Russell, MS, John H. Stewart IV, MD, Konstantinos Votanopoulos, MD, Edward A. Levine, MD, Perry Shen, MD, FACS

Published in: Annals of Surgical Oncology | Issue 8/2014

Abstract

Background

Liver resection has long been considered the standard of care for resectable colorectal hepatic metastases (HM). Patients with colorectal peritoneal surface disease (PSD) are now also being treated with aggressive therapy in the form of cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Methods

A retrospective comparison of optimally-treated colorectal cancer patients with HM or PSD obtained from prospectively maintained databases (1991–2010).

Results

Liver resection was performed on 179 patients with HM, while 93 PSD patients received a complete cytoreduction followed by HIPEC. Patients differed in terms of age, performance status, site of primary cancer, T stage, and the use of perioperative chemotherapy. Five-year overall survival for HM patients was 36 %, with a median survival of 46 months, compared with 26 % and 34 months in patients with PSD (p = 0.024). When stratified by resection status, R0 HM (n = 170) and R0 PSD (n = 48) patients had similar median survival (49 vs. 41 months; p = 0.39). Median survival following R1 resection was also similar among HM (n = 9) and PSD (n = 45) patients (28 vs. 23 months; p = 0.68). Multivariate analysis identified distinctly different independent prognostic factors between HM and PSD patients. Major morbidity was 21 and 23 % (p = 0.88), while mortality was 3.9 versus 5.4 % (p = 0.55) in the HM and PSD patients, respectively.

Conclusion

Colorectal HM and PSD are distinct biologic diseases with different presentations and unique prognostic factors. However, long-term survival following CS/HIPEC is comparable to liver resection when stratified by completeness of resection. Furthermore, perioperative morbidity and mortality are similar.

Available only for authorised users

Eisenberg B, Decosse JJ, Harford F, et al. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer. 1982;49(6):1131–1134.PubMedCrossRef

Dawson LE, Russell AH, Tong D, et al. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol. 1983;22(2):95–99.PubMedCrossRef

Bergmark S, Hafström L. The natural history of primary and secondary malignant tumors of the liver. I: the prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969;23(1):198–202.CrossRef

Bengtsson G, Carlsson G, Hafstrom L, et al. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141(5):586–589.PubMedCrossRef

Finlay IG, Mcardle CS. Occult hepatic metastases in colorectal carcinoma. Br J Surg 1986;73(9):732–735.PubMedCrossRef

(6) Bozzetti F, Bignami P, Morabito A, et al. Patterns of failure following surgical resection of colorectal cancer liver metastases: rationale for a multimodal approach. Ann Surg. 1987; 205(3):264–270.PubMedCentralPubMedCrossRef

Gertsch P: A historical perspective on colorectal liver metastases and peritoneal carcinomatosis: similar results, different treatments. Surg Oncol Clin N Am 2003;12:531–541.PubMedCrossRef

de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250(3):440–448.PubMed

Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer biologic perspectives. Ann Surg. 1989;210(2):127–138.PubMedCentralPubMedCrossRef

10.

Scheele J, Stang R, Altendorfhofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19(1):59–71.PubMedCrossRef

11.

Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–765.PubMedCentralPubMedCrossRef

12.

Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13(5):668–676.PubMedCrossRef

13.

Wang X, Hershman DL, Abrams JA, et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer. 2007;97(12):1606–1612.PubMedCentralPubMedCrossRef

14.

Figueras J, Torras J, Valls C, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007;50(4):478–488.PubMedCrossRef

15.

Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–4580.PubMedCrossRef

16.

Minagawa M, Yamamoto J, Kosuge T, et al. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation. Arch Surg. 2007;142(3):269–276.PubMedCrossRef

17.

Rees M, Tekkis PP, Welsh FKS, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247(1):125–135.PubMedCrossRef

18.

Nathan H, de Jong MC, Pulitano C, et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg. 2010;210(5):755–764.PubMedCrossRef

19.

Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132(5):505–510.PubMedCrossRef

20.

Pawlik TM, Scoggins CR, Zorzi D, et al: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–724.PubMedCentralPubMedCrossRef

21.

Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77(7):1254–1262.PubMedCrossRef

22.

Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer; analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–318.PubMedCentralPubMedCrossRef

23.

McKay A, Fradette K, Lipschitz J. Long-term outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases. HPB Surg. 2009:2009:346963.CrossRef

24.

Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240(3):438–447.PubMedCentralPubMedCrossRef

25.

Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg. 2002;124(5):1007–1013.PubMedCrossRef

26.

Welter S, Jacobs J, Krbek T, et al. Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg. 2007;84(1):203–210.PubMedCrossRef

27.

Mahmoud N, Dunn KB. Metastasectomy for stage IV colorectal cancer. Dis Colon Rectum. 2010;53(7):1080–1092.PubMedCrossRef

28.

Chu DZJ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective-study of prognostic factors. Cancer. 1989;63(2):364–367.PubMedCrossRef

29.

Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–3292.PubMedCrossRef

30.

Knorr C, Reingruber B, Meyer T, et al. Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities. Int J Colorectal Dis. 2004;19(3):181–187.PubMedCrossRef

31.

Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum. 2000;43(10):1341–1346.PubMedCrossRef

32.

Glehen J, Cotte E, Schreiber V, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg. 2004;91(6):747–754.PubMedCrossRef

33.

Verwaal VJ, van Ruth S, Witkamp A, et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12(1):65–71.PubMedCrossRef

34.

Kianmanesh R, Scaringi S, Sabate JM, et al. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg. 2007;245(4):597–603.PubMedCentralPubMedCrossRef

35.

Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg. 2008;248(5):829–835.PubMed

36.

Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92(1):71–76.PubMedCrossRef

37.

Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11(2):178–186.PubMedCrossRef

38.

Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251(5):896–901.PubMedCrossRef

39.

Cavaliere F, De Simone M, Virzi S, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol. 2011;37(2):148–154.PubMedCrossRef

40.

Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15(9):2426–2432.PubMedCrossRef

41.

Shen P, Thai K, Stewart JH, et al. Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol. 2008;15(12):3422–3432.PubMedCrossRef

42.

Cao CQ, Yan TD, Liauw W, et al. comparison of optimally resected hepatectomy and peritonectomy patients with colorectal cancer metastasis. J Surg Oncol. 2009;100(7):529–533.PubMedCrossRef

43.

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6,336 patients and results of a survey. Ann Surg 2004;240(2):205–213.PubMedCentralPubMedCrossRef

44.

Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–685.PubMedCrossRef

45.

Franko J, Ibrahim Z, Gusani NJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–3762.PubMedCrossRef

46.

Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Center Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3): 263–267.PubMedCentralPubMedCrossRef

47.

Sugarbaker P. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14(3):254–261.PubMedCrossRef

48.

Jacquet P, Averbach A, Stephens AD, et al. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55(2):130–138.PubMedCrossRef

49.

Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol. 2005;288(3):F433–F442.PubMedCrossRef

50.

Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003;12(3):689–701.PubMedCrossRef

51.

Los G, Smals OAG, Vanvugt MJH, et al. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res. 1992;52(5):1252–1258.PubMed

52.

Koga S, Hamazoe R, Maeta M, et al. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res. 1984;44(5):1840–1842.PubMed

53.

Scheele J, Altendorf-Hofmann A. Surgical treatment of liver metastases. In: Blumgart LH (ed). Surgery of the liver and biliary tract. 3rd ed. London: WB Saunders, 2000:1475–1502.

54.

Vetto JT, Hughes KS, Rosenstein R, et al. Morbidity and mortality of hepatic resection for metastatic colorectal carcinoma. Dis Colon Rectum 1990;33(5):408–413.PubMedCrossRef

55.

Nordlinger B, Parc R, Delva E, et al. Hepatic resection for colorectal liver metastases influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann Surg. 1987;205(3):256–263.PubMedCentralPubMedCrossRef

56.

Holm A, Bradley E, Aldrete JS. Hepatic resection of metastasis from colorectal carcinoma morbidity, mortality, and pattern of recurrence. Ann Surg. 1989;209(4):428–434.PubMedCentralPubMedCrossRef

57.

Kortz WJ, Meyers WC, Hanks JB, et al. Hepatic resection for metastatic cancer. Ann Surg. 1984;199(2):182–186.PubMedCentralPubMedCrossRef

58.

Olak J, Wexler MJ, Rodriguez J, et al. Hepatic resection for metastatic disease. Can J Surg. 1986;29(6):435–439.PubMed

59.

Bradpiece HA, Benjamin IS, Halevy A, et al. Major hepatic resection for colorectal liver metastases. Br J Surg. 1987;74(4):324–326.PubMedCrossRef

60.

House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–752.PubMedCrossRef

61.

Smeenk RM, Verwaal VJ, Zoetmulder FN. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94(11):1408–1414.PubMedCrossRef

Title: Metastatic Colorectal Cancer: Survival Comparison of Hepatic Resection Versus Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Authors: Aaron U. Blackham, MD
Gregory B. Russell, MS
John H. Stewart IV, MD
Konstantinos Votanopoulos, MD
Edward A. Levine, MD
Perry Shen, MD, FACS
Publication date: 01-08-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 8/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-3563-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Metastatic Colorectal Cancer: Survival Comparison of Hepatic Resection Versus Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2014

Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials

Population-Based Registries are Important in Sarcoma: An Editorial Regarding “Incidence Patterns of Primary Bone Cancer in Taiwan (2003–2010)”

Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors

Identification of Subsets of Patients with Favorable Prognosis After Recurrence in Completely Resected Non-Small Cell Lung Cancer

Thyroglobulin Antibodies Could be a Potential Predictive Marker for Papillary Thyroid Carcinoma

The Frequencies and Clinical Implications of Mutations in 33 Kinase-Related Genes in Locally Advanced Rectal Cancer: A Pilot Study